APP and Alzheimer disease: Such M1 muscarinic agonists appear to be disease-modifying agents in AD [51] while cholinergic modulation of APP via the M1 muscarinic receptor has offered a potential therapeutic route to activate alpha-secretase and thus reduce amyloid and increase the secretion of neuroprotective APP(s) [52,53,54,55,56].